TIG Advisors LLC Decreases Stake in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

TIG Advisors LLC lessened its holdings in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) by 57.9% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 70,709 shares of the company’s stock after selling 97,335 shares during the quarter. TIG Advisors LLC’s holdings in Maravai LifeSciences were worth $385,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of MRVI. Performa Ltd US LLC boosted its holdings in Maravai LifeSciences by 614.3% in the 4th quarter. Performa Ltd US LLC now owns 5,000 shares of the company’s stock worth $27,000 after buying an additional 4,300 shares during the period. FNY Investment Advisers LLC boosted its holdings in shares of Maravai LifeSciences by 600.0% in the fourth quarter. FNY Investment Advisers LLC now owns 7,000 shares of the company’s stock worth $38,000 after acquiring an additional 6,000 shares during the period. Farther Finance Advisors LLC grew its position in shares of Maravai LifeSciences by 3,541.4% in the fourth quarter. Farther Finance Advisors LLC now owns 10,196 shares of the company’s stock valued at $56,000 after purchasing an additional 9,916 shares in the last quarter. Cibc World Markets Corp bought a new stake in shares of Maravai LifeSciences during the 4th quarter valued at $56,000. Finally, Atria Investments Inc bought a new stake in Maravai LifeSciences during the 4th quarter worth approximately $58,000. Hedge funds and other institutional investors own 50.25% of the company’s stock.

Analysts Set New Price Targets

MRVI has been the topic of several recent analyst reports. UBS Group lowered their price target on Maravai LifeSciences from $8.00 to $2.50 and set a “neutral” rating on the stock in a report on Friday, March 21st. Robert W. Baird lowered shares of Maravai LifeSciences from an “outperform” rating to a “neutral” rating and dropped their target price for the company from $9.00 to $3.00 in a research report on Wednesday, February 26th. Bank of America decreased their price target on shares of Maravai LifeSciences from $9.00 to $8.00 and set a “buy” rating on the stock in a report on Monday, March 3rd. Baird R W downgraded shares of Maravai LifeSciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 26th. Finally, Stifel Nicolaus set a $5.00 target price on Maravai LifeSciences in a research note on Friday, March 21st. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $6.34.

Insiders Place Their Bets

In other Maravai LifeSciences news, General Counsel Kurt Oreshack sold 25,000 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $5.03, for a total transaction of $125,750.00. Following the transaction, the general counsel now owns 167,618 shares in the company, valued at approximately $843,118.54. This represents a 12.98 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.63% of the company’s stock.

Maravai LifeSciences Trading Down 2.0 %

Shares of MRVI stock opened at $2.01 on Tuesday. The company has a debt-to-equity ratio of 0.89, a current ratio of 10.74 and a quick ratio of 9.94. The business has a 50-day moving average of $2.41 and a 200 day moving average of $4.56. The stock has a market capitalization of $511.22 million, a PE ratio of -1.23 and a beta of 0.18. Maravai LifeSciences Holdings, Inc. has a 1-year low of $1.67 and a 1-year high of $11.56.

Maravai LifeSciences Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.